Cheaper drug may match expensive biologic in artery disease trial
NCT ID NCT03892785
First seen Nov 26, 2025 · Last updated May 14, 2026 · Updated 17 times
Summary
This study compares two treatments—methotrexate and tocilizumab—for giant cell arteritis, a disease that causes inflamed arteries and can lead to vision loss. Both drugs aim to prevent relapses and reduce the need for long-term steroids, which have serious side effects. About 230 adults with this condition will receive one of the two treatments for 12 months, and researchers will track how many stay relapse-free at 18 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079, France
Conditions
Explore the condition pages connected to this study.